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Background. We tested an original, woman-focused intervention, based on body empowerment, and female-initiated barrier
methods, including the female condom (FC) and cervical barriers. Methods. Eligible women were >= 18 years of age, HIV
seronegative, and active drug users, reporting 30% or greater unprotected sex acts. Both controls (C) and intervention (I)
participants received enhanced HIV/STI harm reduction counseling. I participants underwent 5 additional weekly group sessions.
We compared change in frequency of unprotected vaginal intercourse across arms at 12 months. Results. Among 198 enrolled
women, over 95% completed followup. Two-thirds were African-American; most of them used crack, had a primary partner,
and reported sex exchange. In paired t-tests from baseline to followup, the frequency of unprotected vaginal sex dropped
significantly for I (primary 𝑃 < 0.00, nonprimary 𝑃 < 0.002) and C (primary 𝑃 < 0.008, nonprimary 𝑃 < 0.000) arms
with all partners. The difference in change across arms was of borderline significance for primary partner (𝑃 = 0.075); no
difference was seen for nonprimary partner (𝑃 = 0.8). Use of male condom and FC increased with both partner types over
time, but more consistently among I women. Conclusion: The “value-added” impact of the intervention was observed mainly
with primary partners. Body knowledge with routine FC counseling should be incorporated into interventions for drug-using
women.
1. Introduction
Women have among the highest rates of new HIV infections
globally and the rate of new infections has not lessened in
recent years [1–4]. African Americans account for 66% of
new HIV infections among all US women [5]—over 5 times
their proportion representation (12%) in the population. One
in 30 African-American women can expect to acquire HIV
infection during their lifetime [6]; the vast majority of these
are through heterosexual intercourse.
Crack-using African-American women are a distinct,
hard-to-reach population for whom empowerment to reduce
HIV/STI risk takes on additional complexities due to the
entangled dependencies of drugs, partnerships with men
(who are often drug involved) formaterial support forwomen
and their children, and constant threat of violent reprisal
[4, 7–9]. Concurrent infection with STI is considered to
be endemic among African-American, drug-using, HIV+
women [10].
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Women’s biological inequality in vulnerability to sexually
transmitted infection (STI) can be addressed with greater
availability and use of male and female condoms (FC). In
addition to challenges in the diffusion of available protection
technologies, however, gender inequity in sexual relation-
ships, limited bargaining power of women complicated by
threats of violence, and insufficient resource commitment to
health issues among minorities and the poor all contribute
to women’s continuing entrenchment of HIV/AIDS in the
United States.
The FC is the only female-initiated protection method
that protects against HIV/STI and unwanted pregnancy
at a level equivalent to a male condom (MC; [11]). Full
integration of the FChas lagged far behind inHIVprevention
efforts [12–14]. For example, “best evidence” interventions
for US populations at high risk [15] infrequently (4 of 14
studies) included information and counseling on the FC,
although most studies were targeted to heterosexual risk
groups. Formal CDC documents on voluntary counseling
and testing (VCT) do not specifically refer to FC as integral
to the counseling approach. Adoption of the FC into routine
counseling has been inconsistent and lacking energy.
Effective interventions targeted to drug-using women to
reduce sexual risk are few in number and, as pointed out by
Wechsberg et al. [16], have rarely involved follow-up intervals
of longer than 6 months. Studies with short-term followup
evaluating effective intervention approaches have included
two woman-focused interventions: the Co-Op model [17]
as well as the NIDA standard model tested by Sterk and
colleagues [18], as against two enhanced models.
The Womens’ Co-Op Intervention is a brief 4-session
interventionwithmixed individual and group sessions, based
on empowerment and feminist theory, encouraging women
to understand their HIV risks in the context of substance
abuse and effects on personal power and vulnerability to vic-
timization [17]. Numerous adaptations have been conducted
since the first trial of the intervention, which resulted in
its recognition as a best evidence intervention [15], based
on results from 6-month followup. Long-term followup (4
years) of 60% of the original study population, however,
found evidence of differential attrition favoring the retention
of the high-risk participants and lack of long-term sustained
salutary effects observed at 6 months [16].
Sterk and colleagues [18] followed 333 mainly crack-
using women who were randomly assigned to three different
conditions. With 96% retention at 6 months, positive change
was demonstrated in drug use behavior and sexual risk
behavior, as well as drug-related sexual risk behavior such as
sex trade. However, no differences among theNIDA standard
andwoman-focused interventions were found.The enhanced
interventions were based on five behavioral theories with a
gender- and culture-specific focus. All conditions involved
access to prevention methods and included practice of nego-
tiation and protection techniques and technologies.
The behavioral intervention tested here (“BestBET”) inte-
grated elements from three existing theories—the Theory
of Gender and Power [19], Community Empowerment The-
ory [20], and Risk Reduction/Harm Reduction Theory—
as well as an original theory of “body empowerment.” The
latter draws heavily from feminist health principles espoused
widely in the 1970s in such works as Our Bodies, Ourselves
[21]. The BestBET intervention was initially developed as
a multiple session, clinic-based intervention among HIV+
women [22], and has evolved through a series of studies on
diverse populations of high-risk women [23–25]. Increased
body knowledge appeared to facilitate use of women’s barrier
methods in these studies because risk behavior declined.
We believed that active crack/polydrug users would
attend a relatively long, multisession intervention with
women-focused content despite the inherent physical and
mental challenges involved. We posited that the woman-
specific intervention themes would have cross-cutting rele-
vance and produce positive behavioral change among this
population at very high sexual risk for HIV/STI.
In this paper, we describe a randomized controlled trial of
an intervention (“BestBET”) from a sample of 198 drug-using
womenwith high-risk sexual behavior who were followed for
12 months.
2. Methods
2.1. Intervention. The feminist health model as applied to
HIV underscores the need for holistic education about
reproductive organs and genitals, rather than a narrow focus
onHIV.Our intervention included session content onnormal
female anatomy, the menstrual cycle, pregnancy, menopause,
STI signs and symptoms, female cancers, benefits of screening
(mammography and pap smear), and common surgeries.
The body empowerment approach posits that increased
knowledge, sense of ownership, and pride in the body (“body
knowledge”) are an independent pathway to self-esteem
and to self-efficacy for protection behavior—use of female-
initiated barriers, MC negotiation with partners, and refusal
of unsafe sex.Thus, we introduced to interventionwomen the
entire range of female methods thought possibly to reduce
risk of STI/HIV—female condom, diaphragm, cervical cap,
and spermicides (the study was initiated prior to the findings
concerning vaginal irritation with nonoxynol-9 [26]; we
counseled women to abandon use of spermicides for disease
protection following publication of the findings)—arranged
“hierarchically” according to what was known about protec-
tion level [23] in a harm reduction approach to increasing
protection behavior (i.e., “something is better than nothing”).
We also focused on the need for female solidarity and
mutual support. These four pillars—body knowledge, access
to female initiated methods, emphasis on harm reduction,
and a setting promoting female solidarity—provided the
intervention core components. We integrated content on
female and male barriers in each intervention session, focus-
ing on practical applications of the FC with diverse partners,
including paid sexual transactions (e.g., “cheeking” or oral
application of MC without partner initiation) concomitant
with drug use (e.g., inserting an FC before getting high), and
situations of potentially violent partners (inserting cervical
barrier with spermicide for discreet risk reduction). Women
tried the female barriers at home and shared their experiences
at the following group session, where troubleshooting for
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problems encountered in the initial adoption period was
facilitated by a trained counselor.
The impact of basic body education coupled with access
to a full range of female barrier options on decreasing sexual
risk behavior has not, to our knowledge, been evaluated in
active substance users. For this trial, we enhanced certain
elements and adapted the study to target out-of-treatment
drug users. We added a session dedicated to intimate partner
violence (for paying, nonprimary, and primary partners)
including a module on basic self-defense techniques and
exit strategies and use of protection methods in the context
of forced sex. The intervention was held at a university-
operated, community storefront site with a long history of
provision of HIV counseling and testing in a poor, inner city
neighborhood. The intervention was culturally specific and
woman focused.
The elements of the intervention were (1) small groups
with interactive counseling; (2) trained and certified near-
peer community counselors with a history of substance
abuse and in recovery for at least 2 years; (3) role play
and rehearsal, (4) multimedia educational approaches, such
as videos, audio tapes, brochures, posters, and anatomical
models; (5) active referrals to local service organizations;
(6) access to HIV testing; and (7) training of CBO staff for
community capacity building. Audio tapes of diverse risk
vignettes based on interviews with the target population
and accompanying illustrated handouts were prepared by an
outside nonprofit health organization. We collaborated with
a nearby branch of a national family planning organization
to facilitate diaphragm and cervical cap fittings and offered
patient advocate support to accompany study participants to
clinic appointments.
2.2. Eligibility and Recruitment. To be eligible for the Best-
BET study, we required women to (1) be 18 years of age
or older, (2) be HIV seronegative, (3) report 30% or more
unprotected vaginal or anal sex acts over the preceding three
months (averaged over all partners), (4) report not currently
being in drug user treatment other than with Methadone,
and (5) report that heroin or cocaine were either injected,
snorted, or smoked at least 12 times during the same three-
month interval. HIV serostatus was determined using ELISA
with confirmatory Western Blot. Women were excluded for
psychiatric problems or if they had been in drug treatment
formore than 6months. Because changing drug use behavior
was not an explicit study objective, we did not excludewomen
from attending sessions if they were “high” except if such use
disrupted group dynamics.
Eligible women were recruited in Philadelphia between
November 2001 and August 2003, with the use of a mobile
outreach van staffed with trained interviewers and harm
reduction counselors. The van was parked in designated,
high-risk areas known for crack-selling and smoking activity.
Interested women gave the first written consent to be admin-
istered a 20-minute, confidential prescreening assessment
interview that included demographic and behavioral risk
items as well as to provide locator information. The second
screening assessment was conducted at a community store-
front site that served as an information and referral center
for drug users. Potential participants completed a second
written informed consent procedure for the full study. Study
compensation for each visit was $25. Recruitment and study
methods have, in part, been presented in a prior publication
[27].
This study was approved by and conducted in compliance
with the Institutional Review Board of the University of
Pennsylvania. All enrolledwomenprovidedwritten informed
consent.
2.3. Data Collection and Retention Efforts. Participants com-
pleted a baseline risk assessment instrument delivered via
audio, computer-assisted self-interview (a-CASI) targeting
sexual and drug user behavior over prior 6 months. Partner
types were divided into primary and nonprimary. Addi-
tional baseline data were collected in a face-to-face inter-
view including the following: demographic and reproductive
health history, history of STI, health care insurance, and types
and location of health care services used in past 6 months.
A knowledge quiz on the reproductive system and disease
prevention methods was also administered [28].
Following baseline data collection, all women received
enhanced HIV and STI harm-reduction counseling that
exceeds standard guidelines for HIV voluntary counseling
and testing (VCT); both the MC and FC were taught.
Participants then underwent testing for HIV/STI. At the
posttest session, we randomized HIV-negative women to
intervention or control group.We counseledwomenwith STI
on treatment locations and required these women to bring
written confirmation of treatment for formal enrollment.
We provided HIV-positive women with referrals for further
counseling and care but they were excluded from this study.
Women randomized to the intervention armwere invited
back for five, 3-hour, weekly group sessions within 2 months
of enrollment and were contacted for 6- and 12-month
reunion sessions at community sites. Control participants
received limited case management and the offer of free MCs
and FCs, but no other proactive study intervention. At 6-
and 12-month following enrollment, all assessments were
repeated at the community sites or other locations when
necessary.
Masters’ level interviewers were trained and certified in
VCT and in standardized interviewing techniques. Partic-
ipant contact information was updated at least quarterly.
Intensive retention efforts (phone, mailed correspondence,
and in person) were used to follow participants consider-
ing their mobility, including community outreach, visits to
known crack houses and other hang-outs, and hospital and
prison outreach. Retention challenges were discussed weekly
in study meetings. Using multiple methods and extensive
efforts to locate hard-to-reach participants, the retention rate
was 95% at 12 months.
2.4. Statistical Analysis. To test for differences between the
control and intervention groups at baseline, chi-square for
dichotomous variables and independent sample 𝑡-test for
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continuous variables were conducted for demographic vari-
ables and background characteristics. Univariate analyses
including frequencies and percentages were completed to
describe the total sample and its subsets at baseline and 12-
month follow-up.
Our main outcome variable, frequency of unprotected
vaginal intercourse (monthly), is the focus of this paper.
Data for this analysis were derived from a series of questions
delivered via a-CASI, asking first, the total frequency of acts
during the interval (vaginal, anal, and oral) followed by the
frequency of acts protected byMCor FC, diaphragm, cervical
cap, or spermicide (these latter three related only to vaginal
sex). The remainder was defined as unprotected vaginal sex
acts. Protected and unprotected vaginal sexual acts were
calculated at baseline and at 12-month followup for two types
of partners: primary partners and HIV-negative nonprimary
partners. The number of HIV-positive nonprimary partners
was prohibitively small to include for analysis. A primary
(male) partner was described as “someone you have lived
with or have seen a lot, and to whom you have felt a
special emotional commitment.” nonprimary partners were
defined as “other male partner(s) (not your primary or main
partner).” If a woman answered that she did not have vaginal
sex in the prior interval (this was only possible at followup) or
did not have that type of partner, shewas considered as having
zero frequency of unprotected acts. For this study we used an
intent-to-treat analysis with the inclusion of womenwhomay
not have been sexually active during followup and/ormay not
have had a primary or nonprimary sexual partner.
Pairwise analysis was performed on the outcome variable
separately for primary and nonprimary partners from base-
line to followup, for each intervention arm, which included
generating a paired sampled 𝑡-test (𝑃 < 0.05 was considered
significant). For comparison of intervention versus control
arms, first a “change” variable was calculated in the mean
frequency of unprotected acts between baseline and followup.
The change was then compared across arms. Either paramet-
ric (Student’s t-test) or nonparametric tests (Mann-Whitney
𝑈 test) were used to assess statistical significance, depending
on the normality of distribution. All analyses were conducted
using SPSS version 19.0 (SPSS, Inc., Chicago, Illinois).
3. Results
3.1. Sample Demographics and Risk Behavior. A total of
1134 women were prescreened at the van. Of the 616 eligi-
ble women, 304 (49%) successfully completed the baseline
interviews and specimen collection and were invited to
participate in the BestBET study. Among eligible women
completing baseline interviews (𝑛 = 304), six percent were
HIV positive, and overall STI prevalence was 49% [25]. Of
these women, 227 (75%) returned for enrollment procedures
and were randomized (113 as intervention subjects and 114 as
controls). Twenty-nine women were later excluded based on
contradictory information related to eligibility criteria (see
Figure 1). A slightly greater percentage of eligible women
who completed baseline interviews, as compared to the final
study group, reported drug injection (49% versus 42%) and
somewhat fewer had health insurance (65% versus 70%). A
smaller percentage reported a primary partner (78% versus
83%). Other demographic and behavioral differences were
less significant or nonexistent.
The majority of the study participants were African-
American (see Table 1). Their mean age was just under 40
years. A majority of participants were unemployed with
nearly two-thirds reporting use of food stamps. Approxi-
mately half had a high school diploma or equivalent edu-
cational certificate. Most women had a history of drug
treatment, with crack/rock cocaine and marijuana as the
drugs of choice. Over 40% of women in both arms reported
ever injecting drugs, mainly heroin. Most participants also
had a history of sex exchange. A substantial number reported
recent jail or shelter stay.
Most participants (C 79.8%, I 85.9%) had a primary male
sex partner, and more than half (C 56.6%, I 60.6%) had
both a recent nonprimary male sex partner(s) and a primary
partner. Women with primary partners reported substantial
levels of recent (past 6months) intimate partner violence: 21%
had partners who had made threats on their life, 34% had
been forced to have vaginal or anal sex without a condom,
25% had been punched or hit with something that hurt, and
11% had consulted medical care because of a fight (data not
shown). No significant differences across arms were found.
3.2. Paired Analyses: Baseline to Followup, Control,
and Intervention Arms
3.2.1. Unprotected Vaginal Sex Acts. At baseline, the overall
mean frequency of unprotected vaginal sex acts (all enrolled
women) with primary partners in the past 6 months was
34.3 (median = 12), and with nonprimary, HIV-negative
partners was 22.7 acts (median 0). At 12-month followup, the
overall mean frequency of unprotected vaginal sex acts (all
enrolled women) with primary partners was 15. 6 (median 0);
with nonprimary HIV-negative partners the follow-up mean
frequency was 2.9 acts (median 0). A total of 189 women
completed assessments at 12-month followup (retention rate:
95.4%).
3.2.2. Primary Partner. For the paired baseline-to-followup
comparisons, among controls, for primary partner, baseline
frequency was 32.7 acts; at 12 months this was reduced to
19.3 acts (paired t-test, 𝑃 = 0.008; see Table 2). Among
intervention women, mean of unprotected vaginal acts at
baseline for primary partner was 35.9 and at follow-up was
12.3 (paired 𝑡-test, 𝑃 = 0.000).
3.2.3. Nonprimary Partners. For control women with nonpri-
mary HIV partners, mean baseline frequency of unprotected
vaginal acts was 21.6 acts; at 12-month followup frequency
was 2.5 (paired 𝑡-test, 𝑃 = 0.000). Among intervention
women, frequency of unprotected vaginal acts with non-
primary HIV-partners at baseline was 23.8, and at 12-month
followup was 3.5 (paired 𝑡-test, 𝑃 = 0.002).
A statistical test of the change over time (i.e., reduction
in unprotected acts), per partner type, compared across
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Allocation
Analysis
Followup
Enrollment
Assessed for eligibility (n = 1134)
Excluded (n = 907)
∙ Not meeting inclusion criteria (n = 518)
∙ Declined to participate (n = 0)
interview (n = 281)
∙ No biological specimens (n = 31)
∙ Did not return treatment letter (n = 77)
∙ Other reasons: did not appear for baseline
Allocated to control (n = 114)
∙ Received allocated intervention (n = 114)
∙ Did not receive allocated intervention
∙ Received allocated intervention (n = 113)
∙ Did not receive allocated intervention
Analyzed (n = 99)
∙ Excluded from analysis (contradictory
Analyzed (n = 99)
∙ Excluded from analysis (contradictory
Randomized (n = 227)
(n = 0) (n = 0)
eligibility information) (n = 15) eligibility information) (n = 14)
Allocated to intervention (n = 113)
Lost to followup (n = 5) Lost to followup (n = 4)
Discontinued intervention (n = 0) Discontinued intervention (n = 0)
Figure 1: CONSORT 2010 flow diagram.
arms, indicated borderline significance for primary partners
(𝑃 = 0.075), favoring the intervention arm. For nonprimary
partners, no statistical difference could be detected between
the change observed across the two arms from baseline to
followup (𝑃 = 0.80).
3.3. Use of MC and FC. Proportions of women reporting
MC use were greater in both arms in cross-sectional anal-
yses comparing baseline to followup. MC use with primary
partners was lower than with nonprimary partners across
both arms, at both baseline and followup (Table 3). Interven-
tion women reported MC use with primary partners more
frequently at followup but the difference across arms was
not statistically significant for either primary or nonprimary
partners. MC use with nonprimary partner was reported by
two-thirds (I) and three-quarters (C) of women; the higher
rates in I women at follow-up were achieved despite lower
usage at baseline with nonprimary partners (I versus C). Use
of the FC was also substantially higher at followup than at
baseline in both arms. The lowest proportions of women
reporting FCuse at followupwereCwomenwith nonprimary
partners (7%). Use of spermicide and cervical barriers was
also greater at followup comparedwith baseline for all women
except C women with their nonprimary partners. Very few
protected acts involved spermicide use alone and only 1
woman reported use of a cervical barrier unaccompanied by
eitherMCor FCuse.Thus, followupmethod use as compared
with baseline method use appeared to increase the least
when considering the subgroup “control women-nonprimary
partners.” For I women, by contrast, there were consistent and
substantial differences when comparing baseline to followup,
with both partner types and across all methods.
4. Discussion
Thesample of active, drug-usingwomen in this study demon-
strated large changes in risk behavior over 12-month follow-
up. Frequency of unprotected sex acts dropped significantly
for both study arms, across both partner types.The difference
in frequency of unprotected sex for both study arms was
modified by partner type. For primary partners, that differ-
encewas substantial, although not entirely reaching statistical
significance. Statistical significance would likely have been
realized with greater numbers due to the large variability in
the outcome measure. For nonprimary partners, there was
no observed difference across the study arms; women in
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Table 1: Baseline characteristics by randomization group∗.
Control (𝑛 = 99) Intervention (𝑛 = 99)
Demographic
Age 39.6 ± 7.9 39.5 ± 8.7
Race
White 29.0 26.0
African American 63.0 68.0
Latino 10.0 5.0
Other 10.0 5.0
SES/health care
GED or HS diploma 51.0 52.5
Earns less than $1000 per month 77.6 82.8
Unemployed 92.8 93.9
Receives welfare 52.4 51.4
Receives food stamps 65.6 63.6
Shelter stay—past 6 months 13.2 9.2
Has regular medical provider 78.8 72.4
Has some type of health insurance 73.5 65.7
Has Medicaid 50.0 44.2
Reproductive health history/services
Primary sexual partner only—past 6 months 79.8 85.9
Both primary and nonprimary partners—past 6 months 56.6 60.6
Ever pregnant 96.8 91.2
Mean number of live births 3.25 ± 2.2 3.0 ± 2.3
Pap smear—past 6 months 33.3 39.4
HIV test—past 6 months 32.2 42.4
HIV/STI risk indicators
Past 6 months:
Daily alcohol use 27.3 22.2
Daily marijuana use 12.1 8.1
Daily cocaine use 9.1 6.1
Daily crack use 56.6 46.5
Ever injected drugs 42.4 42.4
Ever exchanged sex for money 80.8 79.8
Ever exchanged sex for drugs 66.7 69.7
∗Data: % except where mean ± SD.
Table 2: Paired comparisons, mean frequency of unprotected vaginal sex, baseline to followup, by partner type (𝑁 = 189; 94 controls, 95
intervention)∗.
Partner type Baselinemean
12-month
follow-up mean
P value; change∗∗
over time
P-value; change∗∗
across arms
Primary partner 34.3 15.6 0.000
Control 32.7 19.3 0.008 0.075
Intervention 35.9 12.3 0.000
Non-primary, HIV-negative partner 22.7 2.9 0.000
Control 21.6 2.5 0.000 0.80
Intervention 23.8 3.5 0.002
∗Absence of acts or no partner equals zero unprotected acts (see Methods).
∗∗Change defined as follow-up frequency − baseline frequency.
ISRN Addiction 7
Table 3: Reported use of protection methods (% of women users) in the prior six months, at baseline and followup, by partner and study arm
(cross-sectional analysis).
Primary partner
Baseline 12-month followup
Control
(𝑛 = 74)
𝑛 (%)
Intervention
(𝑛 = 80)
𝑛 (%)
P
Control
(𝑛 = 42)
𝑛 (%)
Intervention
(𝑛 = 47)
𝑛 (%)
P
Male condom 14 (19) 14 (18) 0.82 14 (33) 20 (42) 0.20
Female condom 3 (4) 5 (6) 0.72 12 (29) 9 (19) 0.24
Spermicide 4 (5) 6 (8) 0.72 6 (14) 10 (21) 0.42
Diaphragm/cervical cap 0 3 (4) 0.25 7 1 (2) 0.34
HIV-negative, non-primary partner
Control
(𝑛 = 64)
𝑛 (%)
Intervention
(𝑛 = 55)
𝑛 (%)
Control
(𝑛 = 28)
𝑛 (%)
Intervention
(𝑛 = 24)
𝑛 (%)
Male condom 60 (94) 38 (69) 0.02 21 (75) 16 (67) 0.51
Female condom 5 (8) 4 (7) 0.74 2(7) 6 (24) 0.13
Spermicide 6 (9) 7 (13) 0.85 1 (4) 5 (20) 0.08
Diaphragm/cervical cap 0 2 (4) 0.47 0 (0) 1 (4) 0.46
both arms reported substantial increases in protection. Our
findings agree with those of others indicating that use of MC
is less frequent with a primary partner than with nonprimary
partners [29]; nevertheless, the results with primary partner
for intervention women are encouraging as these partners
are often considered to pose a greater risk of STI/HIV
transmission to drug-using women [8]. Although both types
of counseling reduced unprotected acts, the “value-added”
impact of the group-based intervention appeared to reside
mainly with primary partners.
In our study, FC use also increased in both arms,
with greater and more uniform increases among I women.
In particular, at followup, fewer C women used FC with
nonprimary partners, with proportions that were signifi-
cantly different from I women. We have previously shown
that introduction to the FC and other female protec-
tion methods promoted MC negotiation and possibly a
greater rejection of unprotected sex [23]. These findings
taken together suggest that our group-based intervention
treatment was superior in encouraging behavior change.
Prior studies among drug-using women have often suf-
fered from short follow-up periods [16]. Our 95% retention
rate at 12 months allowed increased confidence in our
findings.
Study participants who used FC found the method suf-
ficiently practical to use with primary and nonprimary part-
ners. There has been a tendency to discount female barrier
methods as impractical and unacceptable though no wide-
scale evidence supports this contention and indeed there is
evidence to the contrary [13, 14]. Women have potentially
more control over FC (versusMC) use but its impact will only
be realized with strong promotional programs and quality
counseling including outreach activities to men wherever
possible [30] and easy access to continuing supplies, to ensure
adoption and maintenance of the behavior [12]. The FC
should be a regular component of VCT, formalized into easily
accessible counseling guidelines and promoted widely. A
separate analysis of knowledge changes with this intervention
[28] suggests that a key component of FC adoption is
empowerment of women through better knowledge of their
bodies. Such education should be incorporated routinely into
future interventions and programs for drug-using women—
including, importantly, woman-focused drug treatment pro-
grams, still few in number and often lacking a reproductive
health approach [8].
Our body empowerment approach and counselor train-
ing supplied women with key elements to boost the use
of female-initiated methods, including cervical barriers and
devices that are important and relevant to drug-using women
[31] but poorly promoted and underresearched as a dual
protection method [32].
4.1. Limitations. This study had several limitations. Study
participants were selected on the basis of specific criteria
drawn up to concentrate a high level of drug-related and
sexual risk. They agreed and were expected to attend five,
relatively long, intervention sessions and return for follow-
up assessments. Other drug-using populations with a lower
risk profile or less availability for study proceduresmight have
demonstrated different results. All self-reported behavior is
subject to social desirability bias. Nevertheless, we used a-
CASI [33], an established technique to increase the validity
of reporting of sensitive behavior in numerous popula-
tions. Additionally, there was high variability in frequency
of reported unprotected acts at both time points. These
considerations tend to mitigate concerns about reporting
bias, though there is no way of eliminating this possibility.
Comparisons of FC and MC use proportions were cross-
sectional due to high levels of changes in partner and sexual
activity. The last data were collected in 2004, potentially
raising concerns about relevance. Drug-using women con-
tinue to be at extremely high risk for HIV/STI, with large
demonstrated racial disparities, despite successful inroads
made for other at-risk populations in the interim, such
as non-injection-using men who have sex with men [34];
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additional approaches are still urgently needed [35]. Finally,
we did not employ an “attention control” arm, as we designed
two alternative counseling approaches that could be used in
the field; thus changes over time cannot be attributed to the
intervention procedures with complete confidence and may
be due in part to the additional time duration spent with
counselors.
Of concern, we may well have underestimated the impact
of our intervention as compared to MC counseling only,
which is practiced widely. We did not find it ethical to
withhold FC from control participants. Also, our analysis was
based on an intention-to-treat approach; women assigned
to the intervention arm did not necessarily complete all
five sessions. The sample size may have been too small
to detect some changes that were statistically significant—
for example, the differences within main partner across
intervention and control arms. Finally, contamination of the
message across study arms was certainly possible, given the
relatively small geographic recruitment area and overlapping
social networks; this too would have acted to minimize
observed differences across the study arms.
5. Conclusion
The HIV primary prevention landscape is changing, with
oral preexposure prophylaxis (PrEP) as well as postexposure
prophylaxis (PEP) now documented to be valuable tools in
the prevention mix and potentially applicable to drug-using
populations [36]. The potential for reducing sexual risk with
vaginal PrEP for women is still unclear, with conflicting
and recently disappointing results regarding the efficacy of
vaginal tenofovir [37, 38]. A daily, voluntary application of an
antiviral vaginal compoundmay suffer from poor adherence;
long-term intact options may be considerably more effective.
As additional topical microbicidal compounds complete test-
ing, including microbicidally impregnated vaginal devices
[39], the counseling on the use of such methods, especially
among women at high risk such as IDU and NIDU women,
will become more routine. Our results suggest that active
drug-using women at high risk of sexually transmitted
HIV/STI will partake of such counseling and capitalize on
expanded access to these technologies.
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